Title: SENSITIVE AND SPECIFIC ASSAY FOR BABESIA SPP.

Abstract: The invention is directed to methods of using novel Babesia antigen peptides in detecting Babesia spp. in a sample. The methods may be adapted to assays suitable for high blood volume screening, use for clinical diagnosis of patients with babesiosis -is, or assaying blood contaminated with Babesia spp., such as B. microti.
**Sensitive and Specific Assay for Babesia spp.**

**RELATED APPLICATIONS**


**BACKGROUND OF THE INVENTION**

Human babesiosis is a malaria-like illness caused by infection of red blood cells by various species of protozoan parasites of the genus *Babesia*. *B. microti* is responsible for most human infections reported in the United States, and this parasite is endemic in parts of the Northeast and upper Midwest. *B. microti* infections are asymptomatic in most individuals but can lead to severe illness or death, especially in immunosuppressed, asplenic or elderly individuals. The parasite is primarily transmitted to humans by exposure to deer ticks in endemic areas. However, babesiosis can also be transmitted by blood transfusion. The parasite is able to tolerate standard blood banking conditions and adjunct processing procedures (Leiby DA. *Vox Sang* 2006, 90: 157-165) as evidenced by transmission following transfusion of a whole blood, liquid-stored and frozen-deglycerolized red cells, as well as whole blood derived platelets (Pantanowitz L, et al. *Transfusion* 2001, 41: 440). Over 100 cases of transfusion-transmitted babesiosis (TTB) have been reported to the FDA since 1979 and at least 12 fatalities since 2005 (Gubernot DM, et al. *Clin Infect Dis* 2009, 48: 25-30).

Despite being acknowledged as the foremost unaddressed infectious risk to the U.S. blood supply, there is an urgent and unmet need for blood donor screening to be implemented (Herwaldt BL, et al. *Ann Intern Med* 2011, Sep, 2011;155 (5)). Furthermore, with no assay licensed for blood screening and no donor screening strategy in widespread use, TTB continues to pose risk to transfusion recipients in the US.

Blood donations from *Babesia-endemic* areas in the U.S. can exhibit up to 1% seropositivity for *B. microti*, and the distribution of *Babesia* seropositivity is spreading rapidly to adjacent states and elsewhere. Indeed, the *B. microti* species of *Babesia* parasite, hitherto rare in Europe, has been reported in localized regions of Germany and Switzerland, with human seroprevalence between 1% and 9% (Leiby DL et al. *Clin Micro Reviews* 2011, Jan, 24 (1): 14-28).

Babesiosis has a wide spectrum of clinical presentation that is largely governed by immune status of the host. While the majority of naturally acquired infections are either asymptomatic or mild and self-limiting in the immunocompetent host, infection at extremes of
age, in the immunocompromised and/or in individuals with asplenia has a high risk of severe complicated and even fatal disease (Asad S, et al. Transfusion 2009, 49:12, 2564-2573). Transfusion recipients share notable overlap with these high-risk groups and TTB confers an estimated mortality of 5-9%.

The emerging threat of human babesiosis as a transfusion-transmitted disease has led to a consensus by the Food and Drug Administration (FDA) and the American Association of Blood Banks (AABB) that screening of blood donations for Babesia is urgently required for blood safety (Leiby DL, Annals Int Med 2011, Aug, 155). Recent reports showing an alarming increase in transfusion-transmitted babesiosis (TTB), which can cause serious illness or death in immunocompromised patients, underscore this need. Therefore a quick, easy, and sensitive assay for blood screening and detecting Babesia is needed, and as such would facilitate a ready supply of blood that are free of Babesia contamination and safe for use by humans.

Currently no commercial, validated and FDA approved test is available for this pathogen. B. microti is currently detectable by four principal assay methods: microscopic observation of Giemsa-stained blood smears, indirect immunofluorescence (IFA), PCR or xenodiagnosis by hamster inoculation. The assay performances reported for these methods are compared in Table 1. The IFA method, originally described over 30 years ago (Chisholm ES, et al, Am. J. Trop. Med. Hyg. 1978; 27:14-19; Krause PJ, et al. Antibody, J. Infect. Dis. 1994; 169:923-926), remains the only currently available serological method. IFA requires microscopy skills, specific training and access to a fluorescence microscope, which is practical for some reference laboratories, but not a technique amenable to routine use and practice by non-specialists. Examination of thin blood smears for piroplasms similarly requires a microscope and skilled operator and is subject to the same limitations (Leiby DA. Vox. Sang 2006, 90: 157-165.). PCR demands a highly controlled environment to avoid contamination and artifactual results, complex and expensive instrumentation and reagents, and a high degree of training to perform properly.

### Table 1

<table>
<thead>
<tr>
<th>Method</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood smear</td>
<td>84%</td>
<td>100%</td>
<td>100%</td>
<td>62%</td>
</tr>
<tr>
<td>IFA</td>
<td>88% - 96%</td>
<td>90% - 100%</td>
<td>69% - 100%</td>
<td>96% - 99%</td>
</tr>
<tr>
<td>PCR</td>
<td>95%</td>
<td>100%</td>
<td>100%</td>
<td>83%</td>
</tr>
<tr>
<td>Xenodiagnosis</td>
<td>74%</td>
<td>100%</td>
<td>100%</td>
<td>50%</td>
</tr>
</tbody>
</table>

### SUMMARY OF THE INVENTION

In contrast, compared to other available methods of detection such as culture, the assays and methods described herein require no specific training beyond pipetting skills, does not require equipment more sophisticated or costly than pipettors and a microplate reader, is suitable for either low or higher volume testing using existing microplate-based instrumentation or automation which is found in many clinical laboratories, and is easily scalable for large scale production.

In one aspect, the invention feature methods for identifying *Babesia spp.* in a sample, the method comprising:

(a) contacting the sample to a solid support immobilized with at least one *Babesia* antigen peptide selected from the group consisting of a polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 39, 40, 41, or 42;

(b) contacting the product of step (a) with a detectable label linked to a reagent that binds to the captured antibody at a different epitope than the epitope to which (a) binds;

(c) contacting the product of (b) with a substrate under appropriate conditions and for an appropriate amount of time, thereby forming a colored-reaction product; and

(d) detecting the formation of the colored-reaction product as an indication of the presence of *Babesia spp.* in the sample.

In certain embodiments, the method further comprises a wash step after step (a).

In certain embodiments, the *Babesia spp.* is selected from the group consisting of *Babesia bigemina, Babesia bovis, Babesia canis, Babesia cati, Babesia divergens, Babesia duncanii, Babesia felis, Babesia gibsoni, Babesia herpailuri, Babesia jakimovi, Babesia major, Babesia microti, Babesia ovata, and Babesia pantherae.*

In certain embodiments, the *Babesia spp.* is *Babesia microti.*

In certain embodiments, the sample is blood or a blood product.
In another aspect, the invention relates to diagnostic kits for the identification of *Babesia spp.* in a sample, the kit comprising at least one *Babesia* antigen peptide selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, or combination thereof.

In certain embodiments, the diagnostic kit comprises a *Babesia* antigen peptide affixed to a solid support.

In another aspect, the invention relates to an isolated *Babesia* antigen peptide selected from the group consisting of: a) a polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 38, 39, 40, 41, or 42; or b) a polypeptide comprising an amino acid sequence of SEQ ID NO: 38, 39, 40, 41, or 42.

In another aspect, the invention relates to a composition comprising at least one isolated *Babesia* antigen peptide selected from the group consisting of: a) a polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 38, 39, 40, 41, or 42; or b) a polypeptide comprising an amino acid sequence of SEQ ID NO: 38, 39, 40, 41, or 42.

The detection assay described herein does not require sophisticated instrumentation. In one aspect of the invention, the detection assay described presents a rapid and cost-effective approach to screening blood donors and blood products for *Babesia spp.*, such as *B. microti* contamination. Further, in yet another aspect of the invention, the detection assay can be used to support the clinical diagnosis of babesiosis. In one embodiment, the colored reaction product may be read visually. In another embodiment, the colored reaction product may be read using a spectrophotometer or an ELISA reader. The detection assay described herein, provides a positive or negative reading of *Babesia* contamination.

The features and benefits of the assay include a sensitivity-detection of *Babesia* at a sensitivity of 100%, versus IFAT, sensitivity for seropositive babesiosis cases of 100%, specificity with normal donor sera from a non-endemic area of ≥ 99%, and a short assay time and the option of immediate readout using visual evaluation. The flexible format and simplicity of the assay lends itself easily to laboratory automation for batch testing in the blood bank or point of use, e.g. testing in the hospital, doctor’s office, manufacturing plant, or in the field (depending of course on the sample to be evaluated). Thus, the *Babesia* detection assay format is simple and straightforward.
Other Features and advantages of the invention will become apparent based on the following Detailed Description and Claims.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a graph depicting the distribution of absorbances for samples tested in an assay containing all 4 *Babesia* antigen peptides, BMN 1-17A, BMN 1-17B, BMN 1-9A, and BMN1-9B, combined. The confirmed *Babesia*-positive samples show absorbances greater than 1.0 for at least one of the 4 peptides. In contrast, the majority of control samples (from non-endemic areas) show absorbances less than 0.1, and, except for eight samples, less than 0.53 OD; thus, a provisional cutoff of 0.53 would yield a specificity of 98%. Among donors in an area endemic for the parasite, a specificity of 95% was still observed with the same cutoff.

Figure 2 is a graph demonstrating Receiver Operating Characteristic (ROC) analysis for *Babesia* peptide Enzyme-Linked Immunoabsorbent Assay (ELISA) using the four *Babesia* antigen peptides, BMN1-17A, BMN1-17B, BMN 1-9A, and BMN1-9B, indicating 100% sensitivity for confirmed infections and 98% specificity at a cutoff value of 0.53.

Figure 3 is a cartoon depiction of one embodiment of the assay format. The assay is configured in a standard indirect ELISA format, in which *Babesia* antibodies in the serum sample are captured by binding to peptide antigens immobilized in the microplate well. After a washing step, detection of the bound serum antibodies is effected by incubation with a secondary antibody coupled to horseradish peroxidase (HRP) which in turn generates a colorimetric signal.

Figure 4 shows the result of a Western blot of *B. microti* and *B. divergens* MOL patient sera. Patient sera from the Upper Midwest and New England detect proteins that are (1) unique to the parasite lysate and (2) not reactive with normal human serum. Bands (p36-37) may relate to BMN 1-9 by virtue of its co-migration with the band detected on the same lysate with a monoclonal antibody specific for BMN 1-9 (provided by Dr. Jeffrey Priest, CDC). The reactivity of an MO-1 (*B. divergens*) patient serum with individual bands in the *B. microti* lysate suggests that further characterization of antigens may yield a more pan-reactive serodiagnostic assay.

Figure 5 shows a graph of ELISA Absorbance Values for Non-Endemic Donor Sera (1-1000) and IFA-Positive Babesiosis Patient Sera (1001-1072) using *Babesia* antigen peptides, BMN1-17A, BMN1-17B, BMN 1-9A, and BMN1-9B, combined. 1000 non-endemic normal donor sera and 72 confirmed (sero-reactive by IFA) babesiosis patient sera
were tested on an ELISA containing peptides BMN1-17A, BMN1-17B, BMN1-9A, and BMN1-9B with conditions optimized for performance. As a result, we observe a cutoff value of 0.3, with a specificity of 99.5%, an improvement over the previous iteration of the assay presented in Figure 1.

Figure 6 depicts a graph of Figure 2: ELISA Values for Endemic Donor Sera vs. IFA. IFA performed on samples with ELISA absorbance > 0.300. 975 normal donor sera from an area endemic for babesiosis were tested using the same ELISA assay presented in Figure 5. Reactivity among this donor population was 0.9% (9 samples). Of those samples that were reactive by ELISA, 6 were also reactive by IFA.

Figure 7 is a graph demonstrating Receiver Operating Characteristic (ROC) Curve of Babesia microti ELISA. The data for the Babesia peptide ELISA containing BMN1-17A, BMN1-17B, BMN1-9A, and BMN1-9B, performed on the donor pools presented in Figure 5, was subjected to ROC analysis. At an assay cutoff of 0.3 we observe 99.5% specificity and 95.8% sensitivity.

DETAILLED DESCRIPTION OF THE INVENTION

I. Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are provided. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

"Amino acid" is used herein to refer to either natural or synthetic amino acids, including glycine and D or L optical isomers, and amino acid analogs and peptidomimetics.

"Antibody" is used herein to refer to binding molecules including immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen-binding site. Immunoglobulin molecules useful in the invention can be of any class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass. Native antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains. Each heavy chain has at one end a variable domain followed by a number of constant domains. Each light chain has a variable domain at one end and a constant domain at its other end. Antibodies include, but are not limited to, polyclonal, monoclonal, bispecific, chimeric, partially or fully humanized antibodies, fully human antibodies (i.e., generated in
a transgenic mouse expressing human immunoglobulin genes), camel antibodies, and anti-idiotypic antibodies. An antibody, or generally any molecule, "binds specifically" to an antigen (or other molecule) if the antibody binds preferentially to the antigen, and, e.g., has less than about 30%, preferably 20%, 10% or 1% cross-reactivity with another molecule. The terms "antibody" and "immunoglobulin" are used interchangeably.

"Babesia" refers to infectious protozoan species of the Babesia family, including, inter-alia: Babesia bigemina, Babesia bovis, Babesia canis, Babesia cati, Babesia divergens, Babesia duncani, Babesia felis, Babesia gibsoni, Babesia herpailuri, Babesia jakimovi, Babesia major, Babesia microti, Babesia ovate, and Babesia pantherae.

"Babesia antigen peptide" is used herein to refer to a peptide sequence derived from clones of the Babesia BMN1 family, including, but not limited to, BM4, MN-10, BMN1-3B, BMN1-9, BMN1-10, BMN1-11, BMN1-8, MN-10, BMN1-4, BMN1-15, BMN1-7, BMN1-5, BMN1-6, BMN1-12, BMN1-2, BMN1-13, BMN1-3, BMN1-17, BMN1-20, and BMN1-21. The Babesia antigen peptides retain biological activity, e.g., the ability to bind anti-Babesia antibodies. The Babesia antigen peptides can be isolated from native sequences, synthesized by methods known in the art, chemically modified, or conjugated to a polymer and/or capture reagent.

"Bind" or "binding" are used herein to refer to detectable relationships or associations (e.g. biochemical interactions) between molecules.

"Capture reagent" refers to a substance, which interacts with (e.g. covalently binds) a Babesia peptide antigen, or chemically modified form thereof, i.e., two different molecules wherein one of the molecules binds with the second molecule through chemical and/or physical means. The two molecules are related in the sense that their binding with each other is such that they are capable of distinguishing their binding partner from other assay constituents having similar characteristics. The members of the binding pair can be referred to as ligand and receptor (antiligand), a binding pair member and binding pair partner, and the like. Examples include without limitation, antigen and antibody binding pair members, biotin and avidin, carbohydrates and lectins, complementary nucleotide sequences, complementary peptide sequences, effector and receptor molecules, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, bovine serum albumin and the like, a peptide sequence and an antibody specific for the sequence or the entire protein, polymeric acids and bases, dyes and protein binders, peptides and specific protein binders (e.g., ribonuclease, S-peptide and ribonuclease S-protein), and the like. Furthermore,
specific binding pairs can include members that are analogues of the original specific binding member.

"Consensus sequence" is used herein to refer to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See, e.g., Winnaker, *From Genes to Clones*, 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence.

A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Mutations can be introduced randomly along all or part of a natural coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity.

"Detectable label" is used herein to refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, and the like. "Fluorophore" refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range. Particular examples of labels which may be used include fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol, NADPH, beta-galactosidase, and horseradish peroxidase.

"Nucleic acid" is used herein to refer to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.

"Peptide" is used herein to refer to a polymer of amino acids of relatively short length (e.g. less than 50 amino acids). The polymer may be linear or branched, it may
comprise modified amino acids, and it may be interrupted by non-amino acids. The term also encompasses an amino acid polymer that has been modified; for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

"Sample" refers to a mixture. Examples include saliva, urine, hydration fluid, nutrient fluid, blood, blood product, plasma, serum, cerebrospinal fluid (CSF), tissue extract, dialysis fluid, serum, plasma, interstitial fluid, sputum, ocular lens liquid, sweat, milk, synovial liquid, peritoneal liquid, transdermal exudates, pharyngeal exudates, bronchoalveolar lavage, tracheal aspirations, semen, cervical mucus, vaginal or urethral secretions, amniotic liquid, cell, tissue, organ or portions thereof obtained from a subject, such as human, animal, mammal, insect, reptile, and the like.

"Solid support" refers to porous or non-porous support for immobilizing reagents. Examples include membranes (i.e., test strips, dip strips, immunochromatographic strip, dip sticks, Western blots, wicks, Southern blots, Northern blots, dot-blots), pads (i.e., made from CF7 Whatman paper), microarrays, slides, film, and microplates. Solid supports may be comprised of various materials, including polyethylene, nylon, natural macromolecules, polyvinyl sulfone, silica, glass fiber, glass fiber with binder, cellulose acetate, and nitrocellulose (NC).

"Specifically binds" is used herein to refer to the interaction between two molecules to form a complex that is relatively stable under physiologic conditions. The term is used herein in reference to various molecules, including, for example, the interaction of an antibody and an antigen (e.g., a peptide). Specific binding can be characterized by a dissociation constant of at least about 1 x 10 \(^{-6}\) M, generally at least about 1 x 10 \(^{-7}\) M, usually at least about 1 x 10 \(^{-8}\) M, and particularly at least about 1 x 10 \(^{-9}\) M or 1 x 10 \(^{-10}\) M or greater. Methods for determining whether two molecules specifically bind are well known and include, for example, equilibrium dialysis, surface plasmon resonance, and the like.

To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the
reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.

The percent identity between the two sequences is a function of the number of identical positions shared by the sequences and the percent homology between two sequences is a function of the number of conserved positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity and/or homology between two sequences can be accomplished using a mathematical algorithm. In certain embodiments, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available on the world wide web with the extension ggc.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available on the world wide web with the extension ggc.com), using a NWSgapdna CMP matrix and a gap weight of 40, 50, 60, 70; or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly set of parameters (and the one that should be used unless otherwise specified) can be a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5.

The percent identity and/or homology between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:1 1-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

II. Babesia antigen peptides

Described herein are highly specific peptides that can bind to antibodies to certain Babesia antigens. Such novel Babesia antigen peptides were developed based, in part, on a selection of immunodominant antigens from B. microti identified originally by expression cloning described in Homer et al. (Homer MJ, et al. J. Clin. Microbiol. 2003 Feb; 41(2):723-729). The strategy consisted of expression of open reading frames (ORFs) by bacteriophage
display and identification of antigen candidates by reaction with pooled sera from patients diagnosed with babesiosis. Sera from chronically infected SCID mice were subsequently used to select for antigens likely to be shed by the parasite (Lodes MJ, et al. Infect Immun. 2000 May; 68(5):2783-2790). Two antigens, designated BMN1-17 and MN-10, were identified which had high reactivity with babesiosis patient sera and low reactivity with normal donors (U.S. patents 6,569,433B1; 6,451,315B1; 6,306,396B1; 6,214,971B1 and 6,183,976B1).

Recombinant proteins corresponding to BMN1-17 and MN-10 were synthesized. A partial clone of BMN1-17 and a second antigen, BMN1-9, which was related to MN-10 by BLAST analysis, were obtained. BMN1-9 had been previously identified by Luo et al. (Luo Y, et al. Parasitol. Int. 2011; Jun; 60(2):119-125), who reported that reactivity against BMN 1-9 occurred within a week post-infection in experimental animals, and persisted for many months. For this reason, BMN 1-9 was chosen as a candidate antigen for detection of sero-reactivity.

Loa et al. reported the identification of potentially dominant epitopes from BMN1-17 and MN-10 by mapping the protein sequence of these antigens with overlapping synthetic peptides (Loa CC, et al. Curr Method 2004, 49: 385-389; Houghton RL, et al. Transfusion 2002 Nov; 42(11): 1488-1496). Recombinant antigens were observed to show highly non-specific antibody binding, therefore the antigen sequences were analyzed in order to identify shorter peptide candidates.

A repeating motif in BMN1-17 was identified that had two main variants.

```
MDSDTRVLPESLDEGVPHQFSRLGHHSMDASINDEEPSFKIGENDIQPPWEDTAPYHSIDDEELDNSMLRNTAQETSDDHEEGNGKLNTNKSEKTERKSHDTQTPQEIYEEILDNLRLRTAQEIYEREGHKGPKNTNKSEKAERKSHDTQTTQIEICEECEEGHDKINKNKS
GNAGIKSYDTQTQEIYCECEEEGHDKINKNKSAGIKSYDTQTPQETSDAHEEGHD
KINTNKSEKAERKSHDTQTTQIEICEECEEGHDKINKNKSAGIKSYDTQTPQETSADAHEEGHD
HEEHHGNLKNKSGKAGIKSHNTQPLKKDFCCEEGCHGNKPDNERDPSSPDD
DGGCECGMTNHVFDYKTTLLLKSLKTETSTHYYIAMAAIFTISLPCMFKAF
``` (SEQ ID NO: 1)

Repeat unit alignment:

```
KSHDTQTTQIEICEECEEEGHDKINKNKSAGI (SEQ ID NO: 2)
KSYDTQTTQIEICEECEEEGHDKINKNKSAGI (SEQ ID NO: 3)
```
Two immunodominant BMN1-17 epitopes were identified BMN1-17A
GKPNTNKSEKAERKSHTQTTQIECCEECEEGHDKINKNKSGNAGI (SEQ ID NO: 8)
and BMN1-17B KSYDTQTPQETSDAHEEGHDKINTNKSEKAER (SEQ ID NO: 9).
Said epitopes may be modified to yield:

Biotin-PEG(4)-GKPNTNKSEKAERKSHTQTTQIECCEECEEGHDKINKNKSGNAGI (SEQ ID NO: 39)
Biotin-PEG(4)-KSYDTQTPQETSDAHEEGHDKINTNKSEKAER (SEQ ID NO: 40)

A further modification of said peptide sequence to enhance stability may comprise
the substitution of serine for cysteine, resulting in the sequences:
GKPNTNKSEKAERKSHTQTTQIECCEECEEGHDKINKNKSGNAGI (SEQ ID NO: 43)
HQEQQNANDRSNPTGAGGQPNESKKKAVK (SEQ ID NO: 44)

Biotin-PEG(4)-GKPNTNKSEKAERKSHTQTTQIECCEECEEGHDKINKNKSGNAGI (SEQ ID NO: 45)
Biotin-PEG(4)- HQEQQNANDRSNPTGAGGQPNESKKKAVK (SEQ ID NO: 46)

Such a modification, or any modification to enhance stability, solubility, reactivity, sensitivity,
and specificity, may be utilized on any of the peptides isolated or derived from clones of the
Babesia BMN1 family of the present invention.

In addition to the peptides described above, the present invention features Babesia
antigen peptides derived from BMN1-9. The three available cloned sequences for BMN1-9
have differences in their amino- and carboxyl-termini, but share a core homology of 215
amino acids. In order to identify peptide antigen candidates, a library of peptides each 15
amino acids in length, overlapping by 8 amino acids, corresponding to the core homology
BMN1-9 sequence was generated and analyzed.
BMN1-9 Core homology region:

HQEQNNANDCNPTGAGGQPNNESKKKAVKLDDLMDKETKNVCTTVNTKLGVKAKSMLNKLGENSHKEYVAEKTKEIDKNKKFNE

Peptide Library:

HQEQNNANDPvCNPT (SEQ ID NO: 11)
DPvCNPTGAGGQPNN (SEQ ID NO: 12)
GGQPNNESKKKAVK (SEQ ID NO: 13)
KKKAVKLDDLDMKE (SEQ ID NO: 14)
LDLMKETKNVCTTV (SEQ ID NO: 15)
NVCTTVNKLGVKA (SEQ ID NO: 16)
KLGVKAKSMLNKLE (SEQ ID NO: 17)
KLNKLEGSHKEYV (SEQ ID NO: 18)
SHKEYVAEKTKEID (SEQ ID NO: 19)
KTKKEIDESNKKFNE (SEQ ID NO: 20)
NKKFNENLVKIEKK (SEQ ID NO: 21)
VKIEKKKKIKVPAD (SEQ ID NO: 22)
IKVPADTGAVDAV (SEQ ID NO: 23)
AEVDAVDDGVAGAL (SEQ ID NO: 24)
GVAGALSDDLSDIS (SEQ ID NO: 25)
LSSDISAIKTLTDD (SEQ ID NO: 26)
KTLTDDVSEKVSEN (SEQ ID NO: 27)
EKVSENKLDATEASAA (SEQ ID NO: 28)
DDEASATEHTDIKE (SEQ ID NO: 29)
HTDIKEKATLLQES (SEQ ID NO: 30)
TLLQESCNGIGTIL (SEQ ID NO: 31)
GITLTDKLAEYLN (SEQ ID NO: 32)
LAEYLNNDTTQNIK (SEQ ID NO: 33)
TTQNIKKEFDERKK (SEQ ID NO: 34)
FDERKKNLTSKTK (SEQ ID NO: 35)
TSLKTKVENKDEDYV (SEQ ID NO: 36)

Analysis of sera selectively reactive with rBMNI-9 suggested that two nonadjacent peptide stretches possessed immunodominant epitopes, BMN1-9A (HQEQNNANDRCNPTGAGGQPNNESKKKAVK (SEQ ID NO: 37)) and BMN1-9B (NKKFNENLVKIEKKKIKNKVPADTGAEVDAC (SEQ ID NO: 38)). Analysis of the peptide library with a monoclonal antibody directed against BMN1-9 revealed reactivity with a sequence contained within the 9A and 9B peptides.

The *Babesia* antigen peptides of the present invention, while often in a native amino acid sequence may be modified to include conservative amino acid substitutions, in accordance with standard techniques. In addition, fragments of the peptides containing, for example 5, 10, 15, 20 or 25 amino acids may be used in assays described herein.

Isolated *Babesia* antigens peptides may comprise, for example, the amino acid sequences of SEQ ID NOs: 8 or 9, or fragments, modified forms, or combinations thereof; or SEQ ID NO: 37 or 38, or fragments, modified forms, or combinations thereof. The isolated *Babesia* antigens peptides of the present invention may include polypeptides having at least, but not more than 20, 10, 5, 4, 3, 2, or 1 amino acid that differs from SEQ ID NOs: 8, 9, 37, or 38. The isolated *Babesia* antigens peptides may comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99% sequence identity with a BMN1-17 epitope, or portion thereof, e.g. a BMN1-17 epitope having the amino acid sequence of SEQ ID NOs: 8 or 9. The isolated *Babesia* antigens may comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99% sequence identity with a BMN1-9 epitope, or portion thereof, e.g. a BMN1-9 epitope having the amino acid sequence of SEQ ID NOs: 37 or 38.

The *Babesia* antigen peptide may be isolated from a BMN1 clone, or synthesized chemically, or ribosomally in a cell free system, or ribosomally within a cell. Chemical synthesis of peptides may be carried out using a variety of art recognized methods, including stepwise solid phase synthesis, semi-synthesis through the conformationally-assisted re-ligation of peptide fragments, enzymatic ligation of cloned or synthetic peptide segments, and chemical ligation. Merrifield et al. in *J. Am. Chem. Soc.*, Volume 85, page 2149 (1964), by Houghten et al. in *Proc. Natl. Acad. Sci. USA*, Volume 82, page 5132 (1985), and by Stewart
and Young in *Solid Phase Peptide Synthesis*, Pierce Chem. Co, Rockford, Ill. (1984). Native chemical ligation employs a chemoselective reaction of two unprotected peptide segments to produce a transient thioester-linked intermediate. The transient thioester-linked intermediate then spontaneously undergoes a rearrangement to provide the full length ligation product having a native peptide bond at the ligation site. Full length ligation products are chemically identical to proteins produced by cell free synthesis. Full length ligation products may be refolded and/or oxidized, as allowed, to form native disulfide-containing protein molecules, (see e.g., U.S. Patent Nos. 6,184,344 and 6,174,530; and T. W. Muir et al, *Curr. Opin. Biotech.* (1993): vol. 4, p 420; M. Miller, et al, *Science* (1989): vol. 246, p 1149; A.


*Babesia* antigen peptides may be achieved using *in vitro* translation systems. An *in vitro* translation systems is, generally, a translation system which is a cell-free extract containing at least the minimum elements necessary for translation of an RNA molecule into a protein. An *in vitro* translation system typically comprises at least ribosomes, tRNAs, initiator methionyl-tRNAMet, proteins or complexes involved in translation, e.g., eIF2, eIF3, the cap-binding (CB) complex, comprising the cap-binding protein (CBP) and eukaryotic initiation factor 4F (eIF4F). A variety of *in vitro* translation systems are well known in the art and include commercially available kits. Examples of *in vitro* translation systems include eukaryotic lysates, such as rabbit reticulocyte lysates, rabbit oocyte lysates, human cell lysates, insect cell lysates and wheat germ extracts. Lysates are commercially available from manufacturers such as Promega Corp., Madison, Wis.; Stratagene, La Jolla, Calif; Amersham, Arlington Heights, Ill; and GIBCO/BRL, Grand Island, N.Y. *In vitro* translation systems typically comprise macromolecules, such as enzymes, translation, initiation and elongation factors, chemical reagents, and ribosomes.
Babesia antigen peptides may be chemically modified based on linkage to a water soluble polymer and capture reagent. The polymer may have a single reactive group, such as an active ester for acylation or an aldehyde for alkylation, so that the degree of polymerization may be controlled. The water soluble polymer, or mixture thereof if desired, may be selected from the group consisting of, for example, polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol. The binding reagent may be selected from the group consisting of biotin and avidin, carbohydrates and lectins, complementary nucleotide sequences, complementary peptide sequences, effector and receptor molecules, enzyme cofactors and enzymes, and enzyme inhibitors and enzymes.

The Babesia antigen peptides may be chemically modified with a N-terminal biotin-linked via a tetramer of polyethylene glycol as set forth in SEQ ID NOs: 39-42.

1) BMN1-17A:
Biotin-PEG(4)-
GKPNTNKSEKAERKSHDTQTTQEECEEECEEGHDKINKKNKSGNAGI (SEQ ID NO: 39)

2) BMN1-17B

Biotin-PEG(4)-KSYDTQTPQETSDAHEEGHKINTNKSEKAER (SEQ ID NO: 40)

Peptide sequences synthesized:

1) BMN1-9A
Biotin-PEG(4)-HQEQNNANDRCNPTGAGGQPNNESKKKAVK (SEQ ID NO: 41)

2) BMN1-9B
Biotin-PEG(4)-NKKFNENLVIKIEKKKIKVPADTGAEVDAV (SEQ ID NO: 42)

The use of biotinylated peptides offers two advantages. First, the peptides can be immobilized on streptavidin-coated plates, leaving the entire length of the peptide free in solution, thereby increasing accessibility for antibody binding and reducing artifacts due to binding of the peptide directly to the hydrophobic microplate surface. Second, is the strategy allows for multiplexing of different biotinylated peptides in a single well, thus simplifying the assay for the end user and providing the potential for greater sensitivity through combination of complementary antigenic specificities.
The modified *Babesia* antigen peptides may comprise, for example, the amino acid sequences of SEQ ID NOs: 39 or 40, or fragments, modified forms, or combinations thereof; or SEQ ID NO: 41 or 42, or fragments, modified forms, or combinations thereof. The modified *Babesia* antigen peptides may include polypeptides having at least, but not more than 20, 10, 5, 4, 3, 2, or 1 amino acid that differs from SEQ ID NOs: 39, 40, 41, or 42. The modified *Babesia* antigen peptides may comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99% sequence identity with a BMN1-17 epitope, or portion thereof, e.g. a modified BMN1-17 epitope having the amino acid sequence of SEQ ID NOs: 39 or 40. The modified *Babesia* antigen peptides may comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99% sequence identity with a BMN1-9 epitope, or portion thereof, e.g. a modified BMN1-9 epitope having the amino acid sequence of SEQ ID NOs: 41 or 42.

The foregoing exemplary *Babesia* antigen peptide may be chemically modified and adapted with other polymers and/or capture reagents using no more than routine experimentation.

**III. Detection assays**

Provided herein are sensitive and specific ELISA assays for the detection of *Babesia* spp. in blood through measurement of *anti-Babesia* antibodies. The modified *Babesia* antigen peptides can be applied in various quantitative rapid assay formats using simple densitometric analysis of colored-reaction product formation in test zones comprising modified *Babesia* antigen peptide covalently immobilized to a solid support on capture reagents. Such assay formats, include but are not limited to, lateral flow, vertical flow, flow-through, dip-strip, passive diffusion, dot-blot assays, plate-based assays such as filter plate wells, passive diffusion, radial diffusion, microarray, microwell, and bead-filtration assays for the detection of various *Babesia* antibodies and utilizing principles of enzyme immunoassay.

Non-limiting examples of infectious protozoan parasites of the *Babesia* species that may be detected in contaminated blood, include, *Babesia bigemina*, *Babesia bovis*, *Babesia canis*, *Babesia cati*, *Babesia divergens*, *Babesia duncanii*, *Babesia felis*, *Babesia gibsoni*, *Babesia herpailuri*, *Babesia jakimovi*, *Babesia major*, *Babesia microti*, *Babesia ovate*, and *Babesia pantherae*.

Clinical samples that may be tested for *Babesia* contamination include, but are not limited to blood, blood products, platelet units/collections, platelet concentrates, serum,
plasma, other blood fractions, tissue, tissue extracts, urine, lymph, hydration fluid (i.e., IV hydration fluids), nutrient fluid, or imagining agents. Babesia present in the sample may be collected and optionally concentrated by centrifugation or filtration. Alternatively, the sample may be dried or evaporated.

In addition, medical devices, agricultural products, environmental products, and manufacturing products, including process samples, may be tested for Babesia contamination using the assay described herein. Non-limiting examples of medical devices that may be tested are catheters, stents, and IVs. Non-limiting examples of agricultural products include food products and the water supply. Testing of the water supply may be extended from water that is consumed by humans and other animals to water that is used in recreational facilities including swimming pools and lakes. Non-limiting examples of environmental products include machinery that is used for processing a wide array of samples and products consumed and used by humans. Non-limiting examples of manufacturing samples include sterile products and their components and intermediates that are manufactured for medical uses.

The methods and assays may contain at least one Babesia antigen peptides are selected from SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, or any combination thereof. The relative stoichiometry of these peptides may be adjusted in order to maintain high sensitivity while further improving the specificity of the assay.

Assay specificity can be optimized by adjustment of assay components known to affect immunoassay performance, including blocking agents (proteins, detergents, polyvinyls), ionic strength, and pH. For peptide-based ELISAs, the synthesized Babesia antigens can be attached to a solid support, such as a microplate, via a biotin-streptavidin link. This can be accomplished by biotinylating the Babesia antigen either during synthesis or post-synthesis by attachment of biotin to a terminal cysteine residue (added during synthesis if not naturally present) using standard maleimide crosslinkers. Streptavidin can be coated on the microplate. PEGylation of the streptavidin (covalent addition of polyethylene glycol polymer, about 20 kDa MW) may substantially increase the binding density and stability of streptavidin on the microplate, with no adverse effects. In exemplary embodiments, biotin-streptavidin are used for immobilization of the peptides. The timing of each assay step can be adjusted to allow sufficient time for both the reaction kinetics and for the processing workflow needed by automated liquid handing workstations in use in blood screening laboratories.
In an exemplary embodiment, the assay is configured in a standard indirect ELISA format, in which *Babesia* antibodies in the serum sample are captured by binding to peptide antigens immobilized in the microplate well. After a washing step, detection of the bound serum antibodies is effected by incubation with a secondary antibody coupled to horseradish peroxidase (HRP) which in turn generates the colorimetric signal. An important performance improvement over previous versions of this assay was achieved by biotinylating the peptide antigens and immobilizing them by binding to a streptavidin-coated microplate rather than by direct binding of antigens to the microplate (Figure 3). This approach likely reduced steric hindrance to antibody binding and allowed greater flexibility and reproducibility in the assay.

In an alternative embodiment, the assay is configured in the QuickELISA™ format, which enables simultaneous addition of the serum sample and detection reagents to the ELISA well, followed by a single wash step and addition of enzyme substrate. The QuickELISA™ format may offer the advantages of a nearly homogeneous assay with high analytical sensitivity and specificity; however, the development time can be longer than that for a conventional indirect ELISA.

In certain embodiments, assay specificity may be further evaluated with samples considered to be difficult, including those with interfering substances and potentially cross-reactive disease conditions (Table 6).

### Table 6. Possible assay interferences to be tasted.

<table>
<thead>
<tr>
<th>Potentially interfering substances</th>
<th>Potentially cross-reactive conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune antibodies (dsDNA, anti-nuclear antibody (ANA), rheumatoid factor (RF), cytomegalovirus (CMV), human anti-mouse antibodies (HAMA))</td>
<td>Malaria (Plasmodium species)</td>
</tr>
<tr>
<td>Lipemia</td>
<td>Lyme borreliosis (Borrelia burgdorferi)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>Anaplasmosis (Anaplasma phagocytophilum)</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>Toxoplasmosis (Toxoplasma gondii)</td>
</tr>
<tr>
<td>Hemolysis</td>
<td>Rocky Mountain Spotted Fever (Rickettsia rickettsii)</td>
</tr>
<tr>
<td>Bilirubinemia</td>
<td>Tularaemia (Francisella tularensis)</td>
</tr>
<tr>
<td>pH</td>
<td>Infectious mononucleosis (EBV)</td>
</tr>
<tr>
<td>Red blood cells</td>
<td>Syphilis (Treponema pallidum)</td>
</tr>
<tr>
<td>White blood cells</td>
<td></td>
</tr>
</tbody>
</table>

Assay conditions, assay reagents including wash buffer and diluents, may be adjusted to minimize the effects of interfering substances or cross-reactivity to other infectious agents.

**IV. Kits**

Also provided herein are kits for detecting *Babesia spp.*, such as *B. microti*, in a sample. A kit for detecting *Babesia spp.* in a sample may comprise synthesized *Babesia* antigen peptides of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, or
any combination thereof attached to streptavidin-coated microplate.

In certain embodiments, a kit for detecting *Babesia* spp. in a sample may further comprise a positive or negative *Babesia* standard, wherein the standards are obtained from non-endemic and endemic normal sera and infected sera.

In further embodiments, a kit for detecting *Babesia* in a sample may comprise an dilution solution. The kit may also comprise a wash buffer. Alternatively, the kit may provide detectable labeling-substrate dissolved in a stop buffer. In further embodiments, a kit for detecting *Babesia* spp. in a sample may still further comprise instructions for spectrophotometric detection or a color-coded scale for visual evaluation as well as sterile sample tubes for performing the reaction. Reagents in the kit may be provided in individual containers or as mixtures of one or more reagents in a single container. Any of the reagents may be provided as a liquid or as a dry powder (e.g., lyophilized).

The methods and assays of this invention may allow for the combined use of multiple antigens from the same source or genus, multiple antigens from the same species of organism, multiple antigens from different species of organisms, or any combinations thereof.

**EXEMPLIFICATIONS**

The invention, having been generally described, may be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention in any way.

**Example 1: Development of a Sensitive and Specific ELISA for Antibodies to *Babesia microti* in Human Serum**

*Background:* Human babesiosis is a tick-borne parasitic infection caused by several species of *Babesia*, including *B. microti*. The pathogen is endemic to the US Northeast and Upper Midwest. However, transfusion-transmitted infection has been documented for *B. microti* beyond the endemic region, hence the disease is a significant risk to the blood supply. Screening blood donors for *Babesia* has been proposed by the FDA and AABB, but a barrier to implementation of such a program has been the lack of an adequately sensitive and specific assay that is suitable for high-volume screening.

*Methods:* We have developed an ELISA for detection of antibodies to *B. microti* based on the use of *Babesia* antigen sequences originally identified as
immunodominant through phage display screening. We have identified repeat regions in several of these antigens, from which synthetic peptides and recombinant antigens were derived. ELISAs developed using these synthetic or recombinant peptides as antigens were evaluated on a panel of 43 Babesia-positive sera, of which all were confirmed by blood smear and 38 by IFAT, and 400 normal serum samples obtained from an area non-endemic for babesiosis.

**Results:** Parallel ELISAs using synthetic or recombinant Babesia antigens detected 38 out of 38 IFAT-positive Babesia sera using a provisional cut-off. Absorbances for positive samples were >2-fold higher than the cut-off. One serum, which was blood smear-positive but IFAT-negative, was likewise negative by ELISA. Eight out of 400 normal blood donors from a non-endemic area were found reactive by ELISA (99% specificity). Further optimization of the ELISA based on refinement of antigen composition and screening of Babesia sera from clinical cases and blood donors of geographically diverse origin is underway.

**Conclusion:** This ELISA shows promise as a sensitive and highly specific screening test for B. microti infection in blood donors.

**Materials and methods**

Peptides: By sequence analysis, a repeat motif was identified in BMN 1-17 with two main variants. These repeat motifs were identified as putative immunodominant epitopes, and peptides corresponding to the sequences were synthesized with amino-terminal Biotin-PEG(4) derivatization. The resulting Babesia antigen peptides were named BMN1-17A (SEQ ID NO: 39) and BMN1-17B (SEQ ID NO: 40). To identify immunodominant epitopes in BMN 1-9, a peptide library was synthesized corresponding to the BMN 1-9 ORF, consisting of 15-amino acid stretches with a 7 residue overlap (Mimotopes). Screening of the library revealed two candidate immunodominant sequences. These were also synthesized with amino-terminal Biotin-PEG(4) and designated BMN1-9A (SEQ ID NO: 41) and BMN1-9B (SEQ ID NO: 42).

ELISA: Wells were coated with a peptide mixture containing concentrations that had been determined to be optimal both in single-peptide/well and multi-peptide/well assays. Serum samples were diluted 1:100 in buffer, and incubated for one hour at room temperature. To detect reactive samples a monoclonal anti-human IgG-HRP conjugate (Southern Biotech) was diluted 1:10,000 and incubated for 30 min at room temperature. Substrate (TMB) and stop solution were obtained from Moss. Reactions were allowed to develop for 10 min before stopping, and absorbance read at 450 nm within 30 min of stopping. ELISA assays were first
developed using individual peptides, and a final assay configuration using all 4 peptides in a single well was then optimized.

Wells were coated with 4 µg/mL streptavidin followed by a peptide mixture containing 250 ng/mL BMN1-9A, 250 ng/mL BMN1-9B, 50 ng/mL BMN1-17A and 50 ng/mL BMN1-17B. These concentrations had been determined to be optimal both in single-peptide/well and multi-peptide/well assays. Serum samples were diluted 1:100 in buffer, supplemented with 300 nM PEG-biotin to block free biotin-binding sites in the wells, and incubated for one hour at room temperature. To detect reactive samples a monoclonal anti-human IgG-HRP conjugate (Southern Biotech) was diluted 1:10,000 and incubated for 30 min at room temperature. Substrate (TMB) and stop solution were obtained from Moss. Reactions were allowed to develop for 10 min before stopping, and absorbance read at 450 nm within 30 min of stopping. ELISA assays were first developed using individual peptides, and a final assay configuration using all 4 peptides in a single well was then optimized.

Assay sensitivity and specificity:

ELISAs were developed to characterize the BMN1-17A (SEQ ID NO:39) and BMN1-17B (SEQ ID NO:40) peptides using forty-three serum samples, which had been confirmed positive for babesiosis in the laboratories by blood smear, PCR or xenoculture. BMN1-17A reacted with 32 out of 37 sera which were positive by IFAT and confirmed by blood smear or PCR, while BMN1-17B reacted with 23 of the same sera. The combination of both peptides improved total detection by 1 out of the 37 sera, to 33 in total.

BMN1-9A (SEQ ID NO:41) reacted with 30 and BMN1-9B (SEQ ID NO:42) reacted with 29 of the 37 IFAT-positive babesiosis sera. Among non-endemic blood donor control sera, BMN1-9A and BMN1-9B reacted with 4 and 6 samples, respectively. BMN1-17A, BMN1-17B, BMN1-9A and BMN1-9B represent novel, previously unidentified immunodominant antigens within the BMN1 family.

Sensitivity relative to IFA with clinically diagnosed Babesia samples:

Individually the four peptides (BMN1-17A and B, BMN1-9A and 9B) showed sensitivities in ELISA ranging from 76% to 92% (Table 2), but when all four peptides were combined in one assay well they yielded an overall assay sensitivity of 100%, among 38 cases of babesiosis positive by IFAT and confirmed by blood smear or PCR (Table 3).
Table 2: Complementarity between BMN 1-9 and BMN1-17 antigens

<table>
<thead>
<tr>
<th></th>
<th>9A or 9B positive</th>
<th>9A and 9B negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>17A or 17B</td>
<td>31</td>
<td>2</td>
</tr>
<tr>
<td>positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17A and 17B</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3: ELISA vs. IFAT

<table>
<thead>
<tr>
<th>Blood Smear or PCR Positives</th>
<th>IFAT Positive</th>
<th>IFAT Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA Positive</td>
<td>38</td>
<td>0</td>
</tr>
<tr>
<td>ELISA Negative</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

Specificity with donors from a non-endemic region.

Four hundred control serum and plasma samples were obtained from freshly collected from young blood donors living in Arizona and the southwest regions of the U.S. known areas non-endemic for Babesia and based on age have lower probability of travel history outside the non-endemic region. The BMN1-17A and BMN1-17B peptides were shown to be highly specific in this group; only 3 and 2 samples were found reactive by ELISA with BMN 1-17A and BMN 1-17B peptides, respectively. BMN 1-9A and BMN 1-9B reacted with 4 and 6 samples, respectively, from this same group.

The specificity in blood donor sera from a non-endemic area ranged from 98.5% to 99.5% for individual peptides, and 98% for the combined assay (Table 4), although this value could be raised to 99% by modification of the cut-off (see below). The data obtained with the combined-peptide assay represented a performance improvement (specificity of 98% rather than 97%) relative to the results shown in the rows depicting the single BMN1-17A, BMN1-17B, BMN1-9A and BMN1-9B, where the four peptides were assayed individually and the results mathematically combined as a prototype assay.
Specificity with donors from an endemic region:

An additional 200 sera were obtained from blood donors in Rhode Island, an area endemic for babesiosis. Specificity for blood donors in this area was lower, as expected, at 95.5% (Table 5); of the 9 reactive samples in this set, 6 were positive by IFAT, likely due to the inclusion of asymptomatic individuals with a history of prior exposure or infection. As these were unlinked sera from healthy donors, there was no information on possible prior exposure to *B. microti* or subclinical infection, both of which may be expected in an endemic donor population and would contribute to a higher background rate of serological positivity. The data shown in Table 5 were reported as a combination of results from separate assays with the four peptides. The above specificity values were based on a provisional cut-off and may be adjusted based on selection of the cut-off algorithm.

<table>
<thead>
<tr>
<th>Antigen</th>
<th>reactive</th>
<th>nonreactive</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMN1-17A</td>
<td>3</td>
<td>397</td>
</tr>
<tr>
<td>BMN1-17B</td>
<td>2</td>
<td>398</td>
</tr>
<tr>
<td>BMN1-9A</td>
<td>4</td>
<td>396</td>
</tr>
<tr>
<td>BMN1-9B</td>
<td>6</td>
<td>394</td>
</tr>
<tr>
<td>Pooled peptide data (97% specificity)</td>
<td>12</td>
<td>388</td>
</tr>
<tr>
<td>Four peptides in single well (98% specificity)</td>
<td>8</td>
<td>392</td>
</tr>
</tbody>
</table>

Table 5: Reactivity of ELISA antigens with blood donor sera from an endemic area

<table>
<thead>
<tr>
<th>Antigen</th>
<th>reactive</th>
<th>nonreactive</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMN1-17A/B</td>
<td>8</td>
<td>192</td>
</tr>
<tr>
<td>BMN1-9A/B</td>
<td>9</td>
<td>191</td>
</tr>
<tr>
<td>Pooled peptide data</td>
<td>9</td>
<td>191</td>
</tr>
</tbody>
</table>

Assay cut-off determination'.
The distribution of absorbances for samples tested in the assay containing all 4 peptides combined were reported in Figure 1. The confirmed Babesia-positive samples showed absorbances greater than 1.0 for at least one of the 4 peptides. In contrast, the majority of control samples (from non-endemic areas) showed absorbances less than 0.1, and, except for eight samples, less than 0.53 OD; thus, a provisional cutoff of 0.53 would yield a specificity of 98%. Among donors in an area endemic for the parasite, a specificity of 95% was still observed with the same cutoff.

Six of the positives in this group were also positive by IFAT, which was in agreement with reports of seroprevalence of 1-2% in endemic areas. Some of the remaining positives may represent incipient infections; at early stages of infection the immune response was not necessarily strong enough to be detected by serological methods.

A ROC analysis for the four-peptide combined assay indicated 100% sensitivity for confirmed infections and 98% specificity at a cutoff value of 0.53 (Figure 2 and Table 7).

Table 7. ROC analysis for Babesia peptide ELISA

<table>
<thead>
<tr>
<th>Cutoff Value</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Likelihood Ratio</th>
<th>Prev. = 0.09</th>
<th>Prev. = 0.01</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.462</td>
<td>1.00000</td>
<td>0.97750</td>
<td>44.44444</td>
<td>0.50551</td>
<td>1.00000</td>
</tr>
<tr>
<td>0.528</td>
<td>1.00000</td>
<td>0.98000</td>
<td>50.00000</td>
<td>0.82609</td>
<td>1.00000</td>
</tr>
<tr>
<td>0.644</td>
<td>1.00000</td>
<td>0.95500</td>
<td>66.65667</td>
<td>0.56364</td>
<td>1.00000</td>
</tr>
<tr>
<td>0.842</td>
<td>1.00000</td>
<td>0.95750</td>
<td>80.00000</td>
<td>0.88372</td>
<td>1.00000</td>
</tr>
<tr>
<td>1.043</td>
<td>1.00000</td>
<td>0.99000</td>
<td>100.00000</td>
<td>0.90476</td>
<td>1.00000</td>
</tr>
<tr>
<td>1.254</td>
<td>0.97368</td>
<td>0.99000</td>
<td>97.36342</td>
<td>0.90244</td>
<td>0.99748</td>
</tr>
</tbody>
</table>

A specificity of 99% (95% Confidence Interval 97.5-99.7%) can be achieved at a cutoff value of 1.04 with no sacrifice in sensitivity, but a lower cut-off would be more appropriate for the performance range of most colorimetric assays. Modification of assay signal strength by adjustment of reagent concentrations or incubation conditions may allow a slightly lower cut-off, within the absorbance range typical for such ELISA assays, while preserving the clear distinction between positives and negatives - thereby making possible final assay operation at close to 100% sensitivity and 99% specificity. Performance values for the assay with greater statistical accuracy may be determined by testing larger numbers of both positive and negative sera.

A Western blot for antibodies to B. microti based on a lysate of B. microti G1 strain was previously developed, but the identity of individual antigens had not been characterized. Ten to twelve reactive bands with molecular weights ranging from 30-150kDa were seen, with varying band patterns in individual serum samples. As shown in Figure 4, patient sera from the Upper Midwest and New England detect proteins that are (1) unique to the parasite lysate.
and (2) not reactive with normal human serum. Bands (p36-37) may relate to BMN1-9 by virtue of its co-migration with the band detected on the same lysate with a monoclonal antibody specific for BMN1-9 (provided by Dr. Jeffrey Priest, CDC). The reactivity of an MO-1 (B. divergens) patient serum with individual bands in the B. microti lysate suggests that further characterization of antigens may yield a more pan-reactive serodiagnostic assay.

Summary of Results:

Forty-three serum samples from patients with babesiosis confirmed by blood smear, PCR or xenodiagnoses were obtained. Of these, five were seronegative, as determined by IFAT. As expected, these samples are also negative by ELISA. Of the 38 seropositive samples, all were detected by our multi-peptide ELISA assay (Figure 1 and Table 3). Thirty-one of the 38 samples reacted with peptides from both BMN 1-17 and BMN 1-9. Two samples were reactive solely with BMN 1-17, and 5 of the samples were reactive solely with BMN 1-9, suggesting the antigens show a certain degree of complementarity (Table 2).

Among normal donors from a non-endemic area, reactivity was observed in 8 of 400 samples in a format containing four peptides in a single well (Figure 1 and Table 4). ROC analysis was conducted to evaluate assay performance for the purpose of determining sensitivity and specificity (Figure 2 and Table 7). Sensitivity was 100% for confirmed babesiosis cases, and among normal donors, 99% specificity was attained with no loss of sensitivity. The ROC analysis in Fig. 2 indicated that with further optimization, an assay cutoff could be selected that results in assay specificity and sensitivity both >99.

Conclusions:

Sensitivity for seropositive babesiosis cases was 100%. Specificity with normal donor sera from a non-endemic area was >99%. This assay of the present invention was simpler than existing assays for babesiosis (IFA, blood smear), can be performed using techniques and equipment common in most testing laboratories, and could be adapted to high throughput applications.

Example 2: Sensitive And Specific Peptide Based ELISA For Detection Of Antibodies To Babesia microti

Background: Human babesiosis is a tick-borne parasitic infection caused by several species of Babesia, the most common of which is Babesia microti. B. microti is endemic to the US Northeast and Upper Midwest. The FDA’s annual report on blood product deviations described eight cases of transfusion-transmitted babesiosis in 2011, indicating that B. microti-contaminated donor blood is a significant threat to the blood supply. Screening blood donors
for *Babesia* has been under discussion by the FDA and the AABB. A barrier to implementation of such screening has been the lack of a sensitive and specific assay that is suitable for high-volume screening. No licensed tests are currently commercially available.

**Methods:** We have developed a peptide-based microwell ELISA for detection of antibodies to *B. microti*, based on the use of *Babesia* antigen sequences originally identified as immunodominant through phage display screening. Four immunodominant peptides have been identified from sequence analysis and epitope scanning experiments using peptide mini-libraries. The four peptides represent different sequence variants within the BMNI gene family. A single-well ELISA incorporating all four of these peptides has been developed and validated. ELISA sensitivity was tested on a serum panel of human serum samples from 74 *Babesia-*infected study subjects, all of whom were confirmed to have had active *Babesia microti* infection by blood smear or PCR. 72 samples in this panel were seropositive by the indirect Immunofluorescence Assay (IFA) based on a cut-off titer of 1:64. Specificity of the *B. microti* ELISA was assessed on 1000 serum samples obtained from blood donors living in an area non-endemic for babesiosis (Arizona) and on 950 serum samples from blood donors living in a babesiosis-endemic region (southeastern New England).

**Results:** The single-well tetra-peptide ELISA successfully recognized 69 out of 72 IFA-positive babesiosis patient sera using a provisional assay cut-off of 0.300. The assay was non-reactive with 99.5% of blood donors from non-endemic regions, and 99.1% of blood donors from southeastern New England, a *Babesia microti*-endemic region.

**Conclusion:** This ELISA shows promise as a sensitive and highly specific screening test for *B. microti* infection in blood donors, as well as for detection of *B. microti* antibodies to aid in the clinical diagnosis of babesiosis.

**Materials and Methods**

**Peptides:** BMNI-17 and BMNI-9 are two members of the BMNI gene family that have previously been identified as immunodominant by phage display screening 1-3. Two peptides, 17A and 17B, were identified by sequence analysis as the main variant repeat motifs from BMNI-17, and were also previously identified as putative immunodominant epitopes4,5. Peptides 9A and 9B were identified based on screening a peptide library corresponding to the BMW 1-9 ORF with patient sera5.

**ELISA:** Microplate wells were coated with a peptide mixture containing concentrations that had been determined to be optimal both in single-peptide/well and multi-peptide/well assays. Serum samples were diluted 1:100 in buffer, and incubated in wells for one hour at room
temperature. Bound antibodies were detected using a cocktail containing a monoclonal anti-
human IgG-HRP conjugate and a monoclonal anti-human IgM-HRP conjugate (both from Southern Biotech), each diluted 1:20,000 and incubated for one hour at room temperature. Wells were incubated with HRP substrate (TMB, Moss) for 10 min before stopping, and absorbance read at 450 nm within 30 min of stopping. A provisional cut-off of 0.3 absorbance units was applied to interpret results. This cut-off value was derived from the mean ELISA absorbance among 200 non-endemic donors plus 5 standard deviations. The non-endemic donors were included in the group shown in Figure 1.

*IFA*: Slides and reagents for performing IFA to detect seroreactivity to *Babesia microti* were purchased from Fuller Laboratories (Fullerton, CA) and used in accordance with the manufacturer's recommended protocol. Samples were scored as positive if the observed titer was >1:64.

Table 8: ELISA Performance versus IFA on Babesiosis Patient Sera

<table>
<thead>
<tr>
<th>ELISA</th>
<th>Positive</th>
<th>Negative</th>
<th>Positive</th>
<th>Negative</th>
<th>Positive</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFA(1:64)</td>
<td>66</td>
<td>3</td>
<td>65</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFA(1:128)</td>
<td>66</td>
<td>3</td>
<td>65</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFA(1:256)</td>
<td>69</td>
<td>0</td>
<td>66</td>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 9: ROC analysis of ELISA data indicates that a specificity up to 99.8% in a non-endemic donor population can be achieved at a sensitivity of 95.8% vs. IFA at 1:64 cut-off (Figure 7).

<table>
<thead>
<tr>
<th>Cutoff</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>A/(A+C)</th>
<th>D/(B+D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.256</td>
<td>69</td>
<td>10</td>
<td>3</td>
<td>993</td>
<td>0.95833</td>
<td>0.99003</td>
</tr>
<tr>
<td>0.291</td>
<td>69</td>
<td>6</td>
<td>3</td>
<td>997</td>
<td>0.95833</td>
<td>0.99402</td>
</tr>
<tr>
<td>0.356</td>
<td>69</td>
<td>2</td>
<td>3</td>
<td>1001</td>
<td>0.95833</td>
<td>0.99801</td>
</tr>
<tr>
<td>0.451</td>
<td>66</td>
<td>1</td>
<td>3</td>
<td>1002</td>
<td>0.91667</td>
<td>0.99900</td>
</tr>
</tbody>
</table>

Summary of Results:

Sixty-nine of the 74 blood smear-positive babesiosis patient samples were detected by the multi-peptide ELISA assay (Table 8 and Figure 5). Two of the 74 babesiosis patient sera were from early, acute infections. They were seronegative both by IFA, based on a cut-off
of 1:64, and by ELISA (data not shown). The ELISA sensitivity versus IFA at 1:64 cut-off was 95.8%. The ELISA sensitivity was greater than IFA at IFA cut-offs > 1:64 (Table 8). The sensitivity values for ELISA versus IFA were statistically equivalent (p>0.05). Five of 1000 samples (0.5%) from donors living in a non-endemic area were reactive in the ELISA (Figure 5). These samples were negative by IFA. Nine of 950 samples (0.95%) from donors living in an area endemic for babesiosis were reactive by ELISA. Six of these 9 were also reactive by IFA (Figure 6). Receiver Operating Characteristic (ROC) analysis of ELISA data indicates that a specificity up to 99.8% in a non-endemic donor population can be achieved at a sensitivity of 95.8% versus IFA at 1:64 cut-off (Figure 7).

Conclusions:

Sensitivity of the B. microti peptide ELISA was equivalent to that of IFA in blood smear positive babesiosis patient sera. ELISA specificity in normal blood donor sera from non-endemic or endemic areas was >99%, but endemic donors exhibit a significantly higher rate of seropositivity. This microplate ELISA assay is simpler to perform than existing assays for babesiosis (IFA, blood smear), can be carried out using techniques and equipment common in most testing laboratories, generates an objectively read and quantitated result, and could readily be adapted to high throughput donor screening. Large scale studies may be carry out in pre-IND and IND trials comprising donor screening in areas of high and low endemicity, with donor follow up by serological and PCR analyses. The ELISA may be adapted to automated high-throughput systems compatible with blood screening laboratory use.

Incorporation by Reference

All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Also incorporated by reference in their entirety are any polynucleotide and polypeptide sequence which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) on the world wide web with the extension tigr.org and or the National Center for Biotechnology Information (NCBI) on the world wide web with the extension ncbi.nlm.nih.gov.

Equivalents and Scope

It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as set forth in the appended claims. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed in the scope of the claims.
What is claimed is:

1. A method for identifying Babesia spp. in a sample, the method comprising:
   (a) contacting the sample to a solid support immobilized with at least one Babesia antigen peptide selected from the group consisting of a polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 39, 40, 41, or 42;
   (b) contacting the product of step (a) with a detectable label linked to a reagent that binds to the captured antibody at a different epitope than the epitope in (a) binds;
   (c) contacting the product of (b) with an substrate under appropriate conditions and for an appropriate amount of time, thereby forming a colored-reaction product; and
   (d) detecting the formation of a color-reaction product as an indication of the presence of one or more analytes in the sample.

2. The method according to claim 1, further comprising a wash step after step (a).

3. The method of claim 1, wherein the substrate is horseradish peroxidase.

4. The method according to claim 1, wherein the Babesia antigen is selected from the group consisting of SEQ ID NOs: 39, 40, 41, and 42.

5. The method according to claim 1, in which the at least one Babesia antigen detects antibodies against at least one of the Babesia spp. selected from the group consisting of Babesia bigemina, Babesia bovis, Babesia canis, Babesia cati, Babesia divergens, Babesia duncani, Babesia felis, Babesia gibsoni, Babesia herpailuri, Babesia jakimovi, Babesia major, Babesia microti, Babesia ovate, and Babesia pantherae.

6. The method according to claim 1, in which the at least one Babesia antigen detects antibodies against Babesia microti.

7. The method of claim 1, wherein the sample is blood or a blood product.

8. A diagnostic kit for the identification of Babesia spp. in a sample, the kit comprising at least one Babesia antigen peptide selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, or combination thereof.

9. The diagnostic kit according to Claim 8, wherein the at least one Babesia antigen is affixed to a solid support.

10. An isolated Babesia antigen peptide selected from the group consisting of:
a) a polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 38, 39, 40, 41, or 42; or
b) a polypeptide comprising an amino acid sequence of SEQ ID NO: 38, 39, 40, 41, or 42.

11. A composition comprising at least one isolated Babesia antigen peptide selected from the group consisting of:
   a) a polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 38, 39, 40, 41, 42, or combination thereof; or
   b) a polypeptide comprising an amino acid sequence of SEQ ID NO: 38, 39, 40, 41, 42, or combination thereof.
Figure 1

- non-endemic NHS (n=400)
- IFAT-positive Babesia sera (n=38)

O.D. (450nm)

Provisional cut-off

Serum Sample
Figure 2

Babesia IFA-positive sera: n=38

Non-endemic donor sera: n=400
Figure 3

Anti-human IgG-HRP Conjugate

Serum Antibody

Biotinylated Peptide

Streptavidin-coated Plate
Figure 4
Figure 6

[Graph showing O.D. (OD450) values with cut-off levels indicated at various points on the x-axis ranging from 0 to 1000.]
Figure 7

Cut-off = 0.3

Sensitivity

1-Specificity

Cut-off = 0.3
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

GOIN 33/569(2006.01)i, GOIN 33/532(2006.01)1, GOIN 33/543(2006.01)1, GOIN 33/68(2006.01)1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

GOIN 33/569; A61K 39/395; C07K 13/00; A61K 39/002; A61K 39/00; G01N 33/53; C12Q 1/68; A61K 39/018

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS(KIPO internal) & Keywords: Babesia spp., identification, detect, diagnostic kit, antigen peptide, solid support

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 2006-031544 A2 (NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.) 23 March 2006 See claims 1-3, 8, 22, 25.</td>
<td>1-11</td>
</tr>
<tr>
<td>A</td>
<td>US 5273884 A (GALE et al.) 28 December 1993 See claims 1, 37-38.</td>
<td>1-11</td>
</tr>
<tr>
<td>A</td>
<td>WO 90-11776 A1 (UNIVERSITY OF FLORIDA et al.) 18 October 1990 See claims 1, 34.</td>
<td>1-11</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
* "A" document defining the general state of the art which is not considered to be of particular relevance
* "E" earlier application or patent but published on or after the international filing date
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
* "O" document referring to an oral disclosure, use, exhibition or other means
* "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 March 2013 (22.03.2013)

Date of mailing of the international search report

29 March 2013 (29.03.2013)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan City, 302-70 l, Republic of Korea
Facsimile No. 82-42-472-7140

Authorized officer

LEE, Dong Wook
Telephone No. 82-42-481-8163

Form PCT/ISA/210 (second sheet) (July 2009)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 2006-03 1544 A2</td>
<td>23.03.2006</td>
<td>WO 2006-03 1544 A3</td>
<td>23.03.2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2006-03 1544 A3</td>
<td>22.03.2007</td>
</tr>
<tr>
<td>US 5273884 A</td>
<td>28.12.1993</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>WO 90-11776 A1</td>
<td>18.10.1990</td>
<td>AU 5417590 A</td>
<td>05.11.1990</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 05171685 A</td>
<td>15.12.1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 05518916 A</td>
<td>21.05.1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9002546 A</td>
<td>24.04.1991</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (July 2009)